Literature DB >> 23258840

Interval cancers in nasopharyngeal carcinoma screening: comparing two screening intervals after a negative initial screening result.

Feng Chen1, Qi-Hong Huang, Fang Fang, Zhi-Wei Liu, Ke Liu, Shang-Hang Xie, Qing Liu, Ming-Huang Hong, Zhen-Er Liao, Wei-Min Ye, Yi-Xin Zeng, Su-Mei Cao.   

Abstract

OBJECTIVES: To examine the optimal screening interval among the individuals who received a negative Epstein-Barr virus immunoglobulin A antibodies against viral capsid antigen (VCA-IgA) serum test result and who comprised the majority of the population screened for nasopharyngeal carcinoma (NPC).
METHODS: Screening was performed in Sihui, Guangdong, China, offering a repeated screening for participants with an initial negative test either after 4-5 years in one centre (short interval centre), or 9-10 years in another (long interval centre). The characteristics and incidence rates (IRs) of interval NPCs (defined as cases diagnosed outside the screening protocol while within the screening interval) were compared between these two centres. Standard incidence ratios (SIRs) were also calculated using the general Sihui population as the reference.
RESULTS: Seven interval NPCs were detected in the short interval centre (IR: 17.8/10(5) person-years) and 20 in the long interval centre (IR: 20.8/10(5) person-years during the first four years and 43.5/10(5) person-years during the remaining years). The SIR in the short interval centre was 0.43 (95% confidence interval [CI]: 0.17-0.89); SIR in the long interval centre was 0.47 (95% CI: 0.17-1.02) during the first four years and 0.90 (95% CI: 0.49-1.51) during the remaining years. No aggressive interval NPC was observed in the short interval centre; four were identified in the long interval centre.
CONCLUSIONS: The incidence of NPC, especially aggressive NPC, was low during the first few years after a negative screening; the incidence increased to the general population level afterwards. A screening interval of 4-5 years may therefore be more suitable than 9-10 years after a negative VCA-IgA test in NPC screening.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23258840     DOI: 10.1258/jms.2012.012068

Source DB:  PubMed          Journal:  J Med Screen        ISSN: 0969-1413            Impact factor:   2.136


  2 in total

1.  Utility of Epstein-Barr virus (EBV) antibodies as screening markers for nasopharyngeal carcinoma: a narrative review.

Authors:  Sweta Sinha; Brittney L Dickey; Anna E Coghill
Journal:  Ann Nasopharynx Cancer       Date:  2022-06-30

2.  Nasopharyngeal carcinoma incidence and mortality in China in 2009.

Authors:  Zhi-Jian Xu; Rong-Shou Zheng; Si-Wei Zhang; Xiao-Nong Zou; Wan-Qing Chen
Journal:  Chin J Cancer       Date:  2013-07-18
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.